V-CARMA: A tool for the detection and modification of antigen-specific T cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35042811.
- Also identified by DOI 10.1073/pnas.2116277119 and PMC identifier 8795542.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
T cells promote our body's ability to battle cancers and infectious diseases but can act pathologically in autoimmunity. The recognition of peptides presented by major histocompatibility complex (pMHC) molecules by T cell receptors (TCRs) enables T cell-mediated responses. To modify disease-relevant T cells, new tools to genetically modify T cells and decode their antigen recognition are needed. Here, we present an approach using viruses pseudotyped with peptides loaded on MHC called V-CARMA (Viral ChimAeric Receptor MHC-Antigen) to specifically target T cells expressing cognate TCRs for antigen discovery and T cell engineering. We show that lentiviruses displaying antigens on human leukocyte antigen (HLA) class I and class II molecules can robustly infect CD8<sup>+</sup> and CD4<sup>+</sup> T cells expressing cognate TCRs, respectively. The infection rates of the pseudotyped lentiviruses (PLVs) are correlated with the binding affinity of the TCR to its cognate antigen. Furthermore, peptide-HLA pseudotyped lentivirus V-CARMA constructs can identify target cells from a mixed T cell population, suppress PD-1 expression on CD8<sup>+</sup> T cells via <i>PDCD1</i> shRNA delivery, and induce apoptosis in autoreactive CD4<sup>+</sup> T cells. Thus, V-CARMA is a versatile tool for TCR ligand identification and selective T cell manipulation.
Medical subject headings
- Genetic Engineering
- Immunotherapy
- Lymphokines